因子V Leiden与已确诊冠心病患者后续动脉血栓事件无关联:GENIUS-CHD个体参与者数据分析
因子V Leiden与心肌梗死和冠心病死亡复合终点无关联(HR 1.03,95%CI 0.92-1.16),卒中、血运重建、心血管死亡和全因死亡风险亦接近无效值。
要点
- 在已确诊并治疗的冠心病患者中,因子V Leiden不增加后续动脉血栓事件风险。
- 常规检测因子V Leiden不太可能改善该人群的动脉血栓事件风险分层。
- 亚组分析未显示基线特征或传统心血管危险因素分层间的差异。
核心结论
- 因子V Leiden与已确诊冠心病患者后续动脉血栓事件及死亡风险增加无关。
研究设计与样本
- 采用Cox比例风险回归获得年龄和性别校正估计值,固定效应荟萃分析合并。
主要发现
- 3190例(4.6%)为因子V Leiden携带者,其中47例为纯合子。
- 因子V Leiden与心肌梗死和冠心病死亡复合终点无关联(HR 1.03,95%CI 0.92-1.16;I2=28%;P-heterogeneity=0.12)。
- 卒中、冠状动脉血运重建、心血管死亡和全因死亡的风险估计均接近无效值。
临床怎么用
- 对已确诊并治疗的冠心病患者,不推荐常规检测因子V Leiden以进行动脉血栓事件风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies examining the role of factor V Leiden among patients at higher risk of atherothrombotic events, such as those with established coronary heart disease (CHD), are lacking. Given that coagulation is involved in the thrombus formation stage on atherosclerotic plaque rupture, we hypothesized that factor V Leiden may be a stronger risk factor for atherothrombotic events in patients with established CHD. METHODS: We performed an individual-level meta-analysis including 25 prospective studies (18 cohorts, 3 case-cohorts, 4 randomized trials) from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) consortium involving patients with established CHD at baseline. Participating studies genotyped factor V Leiden status and shared risk estimates for the outcomes of interest using a centrally developed statistical code with harmonized definitions across studies. Cox proportional hazards regression models were used to obtain age- and sex-adjusted estimates. The obtained estimates were pooled using fixed-effect meta-analysis. The primary outcome was composite of myocardial infarction and CHD death. Secondary outcomes included any stroke, ischemic stroke, coronary revascularization, cardiovascular mortality, and all-cause mortality. RESULTS: The studies included 69 681 individuals of whom 3190 (4.6%) were either heterozygous or homozygous (n=47) carriers of factor V Leiden. Median follow-up per study ranged from 1.0 to 10.6 years. A total of 20 studies with 61 147 participants and 6849 events contributed to analyses of the primary outcome. Factor V Leiden was not associated with the combined outcome of myocardial infarction and CHD death (hazard ratio, 1.03 [95% CI, 0.92-1.16]; I2=28%; P-heterogeneity=0.12). Subgroup analysis according to baseline characteristics or strata of traditional cardiovascular risk factors did not show relevant differences. Similarly, risk estimates for the secondary outcomes including stroke, coronary revascularization, cardiovascular mortality, and all-cause mortality were also close to identity. CONCLUSIONS: Factor V Leiden was not associated with increased risk of subsequent atherothrombotic events and mortality in high-risk participants with established and treated CHD. Routine assessment of factor V Leiden status is unlikely to improve atherothrombotic events risk stratification in this population.
引用
- Mahmoodi BK, Tragante V, Kleber ME, et al. Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. Circulation. 2020. PMID: 32654539. doi:10.1161/CIRCULATIONAHA.119.045526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。